D&D Pharmatech noted that it has successfully completed Phase 2 clinical trials of the metabolically associated steatotic hepatitis (MASH) treatment "DD01" in the United States, leading to a strong stock performance.
D&D Pharmatech's shares traded at 118,200 won in the pre-market at 8:24 a.m. on the 16th, up 20.98% (25,000 won) from the closing price of 97,700 won on the 13th. The Phase 2 clinical trial results of DD01 have spurred investor sentiment.
D&D Pharmatech conducted the study involving 67 patients with overweight and obesity accompanied by MASH and metabolic-associated steatotic liver disease (MASLD) at 12 clinical trial sites in the United States.
The Phase 1 primary endpoint confirmed that 75.8% of patients administered DD01 experienced more than a 30% reduction in liver fat compared to before treatment. This result was statistically significant compared to the placebo group at 11.8%. Additionally, the average liver fat reduction rate in the DD01 treatment group at week 12 was 62.3%, which showed a much faster reduction effect than the placebo group's average of 8.3%.
Given that DD01 demonstrated a superior liver fat reduction effect in this clinical trial, D&D Pharmatech expects it will positively influence future licensing (LO) agreements.
D&D Pharmatech also plans to continue clinical trials and conduct tissue biopsies to determine whether it meets the U.S. Food and Drug Administration's (FDA) MASH approval requirements after 48 weeks of administration. D&D Pharmatech anticipates that relevant results may be announced in the first half of 2026.